MANTA Vascular Closure Device; MANTA Vascular Closure Device, 18F; MANTA Vascular Closure Device, 14F; MANTA SF Depth L
Teleflex Medical LLC · Decision date Aug 5, 2025
What did the FDA decide?
FDA records P180025/S014 as a supplement to PMA P180025, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 5, 2025.
FDA approval order statement
a change to conduct the final release testing of the Manta VCD product family in a new location within the same facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 5, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180025/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Teleflex Medical LLC
- Product code
- MGB
- Decision code
- OK30
- Decision date
- Aug 5, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Teleflex Medical LLC
- Product code
- MGB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180025/S014 received
Application receipt date recorded by FDA.
P180025/S014 · FDA decision
30-Day Notice
P180025/S015 · Related supplement
MANTA Vascular Closure Device
P180025/S016 · Related supplement
MANTA Vascular Closure Device
Timeline entries are records held by MedtechLedger for P180025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MANTA Vascular Closure DeviceP180025/S015 | Teleflex Medical LLC | PMA supplement | Feb 27, 2026 | FDA |
MANTA Vascular Closure DeviceP180025/S016 | Teleflex Medical LLC | PMA supplement | Apr 23, 2026 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Teleflex Medical LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3015 Carrington Mill Blvd., Morrisville, NC, 27560
Sources and methodology
- Original FDA record: P180025/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


